



Exploring Efforts in Europe to Integrate Clinical Research with Clinical Care

Jesper Kjær, Global Director for Public, Private Partnerships, Novo Nordisk A/S



Meet the Speaker

Jesper Kjær

Title: Global Director for Public, Private Partnerships

Organization: Novo Nordisk

Global Head of Public, Private Partnerships at Novo Nordisk.

Co-lead for TransCelerate EHR connectivity workstream. Steering Board member of HL7 Vulcan.

National Advisory to the Danish Ministry of Health and Interior for One Entry Point to Danish Health Data.

Former co-chair for HMA / EMA Big Data Steering Group and Director of the Danish Medicines Agencies Data Analytics Centre (DAC).

25+ years experience in academia, industry and regulatory.

Disclaimer and Disclosures

• The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC.





Agenda

- 1. EU Framework programmes
- 2. Europe Digital Decade and European Health Data Space (EHDS)
- 3. Projects towards EHDS
- 4. IHI projects: a peek into the future
- 5. Conclusion

Exploring Efforts in Europe to Integrate Clinical Research with Clinical Care

- European Union / Commission has for several decades supported research in Europe through Framework Programmes (FP)
- Focus for many of the initiatives under these FPs has been to create cross border collaboration, elevate research and create innovation leading to new jobs
- Since 2012 under this also the worlds largest public, private partnerships frameworks: Innovative Medicines / Health Initiative (IMI, IMI2, IHI) has been funded





EU Framework programmes



⊕ EN

Q Search

Public Health

Home

> Fundir

EU4Health programme 2021-2027 – a vision for a healthier European Union

EU4Health programme 2021-2027 – a vision for a healthier European Union

Two important instruments under EU4Health:

Horizon Europe Innovative Health Initiatives





Research and innovation



EN

Horizon Europe

4. Health

(European Commission Decision C(2024) 2371 of 17 April 2024)

Work Programme 2023-2025

Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society169 Call - Tools and technologies for a healthy society (Single stage - 2023)172

HORIZON-HLTH-2023-TOOL-05-09: Developing a Data Quality and Utility Label for the

HORIZON-HLTH-2023-TOOL-05-01: Clinical trials of combined Advanced Therapy

HORIZON-HLTH-2023-TOOL-05-03: Integrated, multi-scale computational models of patient patho-physiology ('virtual twins') for personalised disease management 175 HORIZON-HLTH-2023-TOOL-05-04: Better integration and use of health-related real-

HORIZON-HLTH-2023-TOOL-05-05: Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care delivery 182 покідом-пштп-2025-100L-05-08: Pandemic preparedness and response: in vitro

fundi

ancial for H

Call - Tools and technologies for a healthy society (Two stage - 2024)189

Conditions for the Call 190 HORIZON-HLTH-2024-TOOL-05-06-two-stage: Innovative non-animal human-based

diagnostic devices to tackle cross-border health threats...

Call - Tools and technologies for a healthy society (Single stage - 2024)193

Conditions for the Call 194 HORIZON-HLTH-2024-TOOL-11-02: Bio-printing of living cells for regenerative

Destination 6. Maintaining an innovative, sustainable and globally


competitive health industry......198

Innovative Health Initiative (IHI)

Transforming research to innovation

- Formerly the Innovative Medicines Initiative (IMI)
- World's largest Public-Private Partnership framework within health technology and life sciences





Real World Data in IMI & IMI2

https://www.ihi.europa.eu/projects-results/project-factsheets/

























https://www.ihi.europa.eu/projects-results/project-factsheets/ehr4cr

Facts & figures

Start Date 01/03/2011

End Date 29/02/2016

Call IMI1 - Call 2

Grant agreement number 115189

Type of Action:

RIA (Research and Innovation

Action)

Contributions €
EU funding 7 194 044

EFPIA contribution 7 555 883

Other 1 893 502

Total Cost 16 643 429

Objective:

Develop a platform to reuse electronic health records for clinical research while ensuring data privacy and security.

Focus:


Interoperability of EHRs, data integration, and use in clinical trials.






Europe Digital Decade and European Health Data Space (EHDS)

Europe's Digital Decade: digital targets for 2030





Digitalisation of public services

Key Public Services: 100% online

Europe's Digital Decade: digital to X

commission.europa.eu/strategy-and-policy/priorities-2019-2024/eur...

Digital transformation of businesses

e-Health: 100% of citizens have access to

medical records online

Digital Identity: 100% of citizens have access to

digital ID



A common European Health Data Space (EHDS)

Separation Skills

| Separation | Skills | Stills | Still






"The EHDS will be a crucial component of a strong European Health Union. It will enable EU-wide collaboration for better healthcare, better research and better health policy making. I invite all interested citizens and stakeholders to take part in the consultation and help us leverage the power of data for our health. This will have to rest on a strong foundation of non-negotiable citizens' rights, including privacy and data protection."

Stella Kyriakides, Commissioner for Health and Food Safety



From DIA Euro 2023: The European Health Data Space (EHDS): Can this Legislation unlock the Power of Health Data to Stimulate Innovation in Europe?, Tom Brookland, EU Data Policy Lead, Hoffmann La Roche, Switzerland


The EHDS History



From DIA Euro 2023: The European Health Data Space (EHDS): Can this Legislation unlock the Power of Health Data to Stimulate Innovation in Europe?, Tom Brookland, EU Data Policy Lead, Hoffmann La Roche, Switzerland



The EHDS: Another Policy in a Rapidly Evolving and Highly interconnected Data and Digital Policy Landscape



The EHDS is also connected to many other EU initiatives: EU Pharmaceutical Legislation, Europe's Beating Cancer Plan, EU MDR and IVDR, European Digital Identity initiative, DARWIN, TEHDAS...






European Health Data Space

Harnessing the power of health data for people, patients and innovation



Main challenges in harnessing the power of health data





European Health Data Space (EHDS)

OBJECTIVES

Effective use of health data

SCOPE & EXPECTED IMPACT

Use of health data (primary, MyHealth@EU)

- Empower individuals to control their data
- Standardization and mandatory certification of EHR systems
- Voluntary labelling of wellness apps
- European Electronic Health Record Exchange Format

Re-use of health data (secondary, HealthData@EU)

- · Health data access bodies
- Purposes for use and forbidden use
- Data permits, secure environments, no identification

Single market for health data, data protection, free movement of people, digital goods and services

Facilitated Research & Innovation

Better Policy Making

MEANS


Legal / Governance

Quality of data

Infrastructure

Capacity building/digitalisation (MFF)







Projects towards EHDS

EU projects to support and develop EHDS

























TEHDAS2 joint action advances the cross-border secondary use of health data in Europe to improve research, innovation and policymaking.



What is our goal?

Our goal is to develop common guidelines and technical specifications to facilitate smooth access to health data and strengthen European collaboration in using data efficiently. Secondary use of health data enhances competitiveness of European research and innovation in the health sector.

https://tehdas.eu/wp-content/uploads/2024/09/tehdas2-brief-leaflet-7.pdf





- 1. Draft guideline for Health Data Access Bodies on **fees and penalties for non-compliance** regulated to the EHDS regulation
- 2. Draft guideline for Health Data Access Bodies on minimum categories and limitations on the reuse of health data
- 3. Draft guideline for data holders on making personal and non-personal electronic health data available for reuse
- 4. Draft guideline for Health Data Access Bodies on the procedures and formats for data access
- 5. Data Access Application Management System (DAAMS) Draft technical specification for health data access bodies
- 6. Draft technical specification for Health Data Access Bodies on data minimisation and de-identification
- 7. Draft technical specification for Health Data Access Bodies on the implementation of the common IT infrastructure
- 8. Draft technical specification for Health Data Access Bodies on the implementation of secure processing environments
- 9. Draft guideline for Health Data Access Bodies on implementing opt-out from the secondary use of health data
- 10. Draft guideline for Health Data Access Bodies on implementing the obligation of **notifying the natural person on a significant finding from the secondary use of health data**





Use cases







Comparing Nationwide He to evaluate European interoperabil an application to cardiom

Led by



Deliverable 9.1

Use Cases report

December 2024





xShare: Expanding the European EHRxF to share and effectively use health data within the EHDS



xShare vision:



Everyone can share their health data in EEHRxF with a click-of-a-button in the European Health Data Space



- Three are the main elements of implementing this vision:
 - The Button (the yellow button): illustrates this capability
 - The HUB (the EHRxF HUB): brings together global standards with industry and government to steward EHRxF specifications and accelerate adoption
 - The Label (the industry label): demonstrates the commitment and capability
 of the industry to implement EEHRxF

The xShare Consortium































IHI projects: a peek into the future

IHI projects: a peek into the future



Testing, improving, and co-creating Guidance and Tools for Real World

Evidence Generation and Use for Decision-Making in Europe





Topic 3: Al-Powered Signal Detection in Pharmacovigilance



Safeguarding innovation in secondary use of health data in the European Health Data Space (EHDS) HORIZON-JU-IHI-2025-10-02-two-stage



RWE Guidance from regulatory and HTA bodies



FDA, USA

2017 - Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

2018 - Use of Electronic Health Record Data in Clinical Investigations

2021, draft - Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision- General principles on plan, design, and analysis of Making for Drug and Biological Products

2021, draft - Assessing Registries to Support Regulatory Decision-Making for Drug and Biological **Products**

2021, draft - Data Standards for Drug and Biological **Product Submissions Containing Real-World Data**

2022 - Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and **Biological Products**

2023, draft - Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products

2023 - Considerations for the Use of RWD and RWE To Support Regulatory Decision-Making for **Drug and Biological Products**

2024, draft - RWE: Considerations regarding NIS for Drug and Biological Products

EMA, EU

2021 - Guideline on registry-based studies 2023 - Data Quality Framework for EU medicines regulation

ICH, M14

pharmacoepidemiological studies that utilize RWD for safety assessment of medicines



2023 - Guide on Methodological Standards in Pharmacoepidemiology, Rev. 11

Swissmedic, CH

2023 - Swissmedic position paper on the use of real world evidence

HAS, FR

2021 - Real-world studies for the assessment of medicinal products and medical devices

MHRA, UK

2021 - Guidance on the use of RWD in clinical studies to support regulatory decisions

2021 - Guideline on randomized controlled trials using RWD to support regulatory decisions



Health Canada

2018 - Use of Electronic Health Record Data in Clinical Investigations

Canada's D&HTA* (+ Health Canada)

2023 - Guidance for reporting RWE

PMDA, Japan

2014 - Guidelines for the conduct of pharmacoepidemiological studies in drug safety assessment with medical information databases

2017 - Basic Principles on the use of medical information databases in post-marketing pharmacovigilance

2020 - Points to consider for ensuring the reliability of post-marketing database study for regenerative medical products

2021 - Basic Principles on utilization of registry for applications



2021 - Guidance for Real-World Data Used to Generate Real-World Evidences (Interim)

2022 - Guidance on the Use of Real-World Evidence to Support Drug Development and **Regulatory Decisions**

2023 - Guidance on Communication with Regulatory Agency on Real-World Studies to **Support Product Registration**

2023 - Guidance on the Design and Protocol Development of Real-World Studies for Drugs

* Health Technology Assessment Agency

Conclusions

Europe has 2030 focus on a digital decade and under this to enable EHDS

The solutions to EHDS are being established through both national investments but moreover through common approaches agreed via the different projects under EU4Health

It is estimated that savings in health care can reach 11 billion Euros over a decade across the EU through better use of data

Horizon Europe and IHI have a range of initiatives that will drive the development of EHDS and a better integration of clinical research with clinical care through the primary and secondary use of data



Thank You!

